|Bid||127.09 x 800|
|Ask||127.13 x 1100|
|Day's Range||127.08 - 127.69|
|52 Week Range||118.62 - 148.32|
|PE Ratio (TTM)||281.28|
|Earnings Date||Oct 16, 2018|
|Forward Dividend & Yield||3.60 (2.86%)|
|1y Target Est||143.45|
Burke Financial Strategies CEO John Burke on the reports that some U.S. companies are shipping goods overseas before they have to start paying tariffs. Burke also discussed how stocks have lagged behind earnings.
Wall Street's just dinged two of them and rewarded the third -- but Motley Fool analysts take a longer view.
LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want access to our free earnings report on Johnson & Johnson (NYSE: JNJ) ("JNJ”"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company reported its financial results on July 17, 2018, for the second quarter of the fiscal year 2018, ended June 30, 2018. The Company surpassed analysts’ estimates for earnings and revenues in Q2 FY18.
Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.
The FDA approves Johnson and Johnson's (JNJ) darunavir-based single-tablet regimen, Symtuza, for the treatment of type 1 HIV-1 in treatment-naive and certain virologically suppressed adults.
Investors should closely watch the movement of the Johnson & Johnson and keep a close eye on ETFs having double-digit allocation to this diversified drug maker.
The university and health care giant are creating a life sciences network hub called JPOD@Philadelphia at the Pennovation Center.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on July 17) Avid Bioservices Inc (NASDAQ: CDMO )( reversed to a profit ...
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Johnson & Johnson saw a pop after announcing second quarter results and vowing to appeal a court order last week that ordered the company to pay a whopping $4.69 billion to nearly two dozen women who alleged the company's talc products contained asbestos and caused them to develop ovarian cancer. Shares of Avid Bioservices also saw big gains after announcing a new CFO. Johnson & Johnson shares saw a gain of 3.54% by the close on Tuesday on trading volume nearly double compared to usual.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting JNJ. Over the last one-month, outflows of investor capital in ETFs holding JNJ totaled $1.74 billion.
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
SINGAPORE (AP) — Asian markets climbed higher on Wednesday as a sweep of positive news from Wall Street and beyond boosted confidence in the U.S. economy.
Strong sales of Johnson & Johnson’s cancer drugs and other medicines helped boost the company’s revenue and earnings for the latest quarter, but the health-products giant’s U.S. consumer business continued to struggle. Sales in the pharmaceuticals unit rose 19.9% globally, the largest increase among J&J segments. Cancer-drug sales rose 42.2%, helped by big gains for the Zytiga prostate-cancer drug and Darzalex, a blood-cancer treatment. J&J’s pharmaceutical sales topped analysts’ expectations despite what executives said was a continued decline in average net U.S. pricing after discounts and rebates.
Shares of Novartis (NVS) added just 0.14% during regular hours Tuesday, the last day of trading before the pharma giant releases its latest quarterly earnings report. Here's what to expect tomorrow morning.
You combine a Fed Chairman who doesn't want to throw us into a recession, which has suddenly become a big worry, with the absence of negative trade news and you get a pretty wild rally in not two but three oppositional groups, something that's not supposed to be happening and historically almost never does. First, let's take the camp that says forget what the Fed says about economic growth, the Treasury yield curve is almost inverted and that means a recession must occur.
On a day stocks climbed following optimistic comments by the chairman of the Federal Reserve, Netflix reported disappointing subscriber additions, and Johnson & Johnson rose on strong pharmaceuticals sales.
Stocks notched another day of gains on Tuesday, on a day when there was little in the way of market-moving news. The Dow Jones Industrial Average gained 55.53 points, or 0.22%, to 25,119.89, while the S&P 500 is up 11.12 points, or 0.40%, to 2809.55 and the Nasdaq Composite added 49.40 points, or 0.63%, to 7855.12. Part of it may have been a "no news is good news," sort of mentality, as Federal Reserve Chief Jerome Powell's dry testimony before the Senate Banking Committee seemed to indicate that the Central Bank was committed to staying the course and markets largely shrugged off earnings reports on a relatively quiet day.
Rating Action: Moody's assigns B2 CFR to MedPlast Holdings, Inc. New York, July 17, 2018 -- Moody's Investors Service ("Moody's) assigned a B2 Corporate Family Rating (CFR) and B2-PD Probability of Default Rating to MedPlast Holdings, Inc. ("MedPlast"). Moody's also assigned a B1 rating to the company's first lien credit facilities comprised of a $70 million revolving credit facility and a $500 million first lien term loan and a Caa1 rating to the company's $225 million second lien term loan.
Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., down $21 to $379.48 The streaming video company's second-quarter subscriber gains were weaker than analysts expected. Johnson & ...
Wall Street stocks rose on Tuesday, with the Dow Jones Industrial Average posting its fourth consecutive session of gains after Federal Reserve Chairman Jerome Powell expressed an optimistic U.S. economic ...